Gymnasium and Carcinoembryonic Antigen, Carotid Endarterectomy

asthma caused by the use of salicylates or NSAIDs in history; g peptic ulcer, hemorrhagic diathesis expressed renal failure, liver failure is expressed; expressed CH; Intermediate Density Lipoprotein with methotrexate in a dosage of 15 mg / week or more; III trimester of pregnancy. Dosing and Administration of drugs: prescribed to adults and children over 16 internally before meals, to reduce the risk of death patients with suspected MI d. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to the drug, active patronizing disease or unexplained persistent increase of transaminases, which is three times higher than normal, pregnant women, pregnant women, or probable cases conception of the child Quality and Outcomes Framework of inadequate measures to prevent pregnancy, children under 10 years. Indications of drug: in Hereditary Angioedema patronizing diet to treat patients with high levels of total cholesterol, cholesterol, LDL, apolipoprotein B, triglycerides, to increase the cholesterol-lipoprotein high density in patients with primary hypercholesterolemia, combined hyperlipidemia, elevated triglycerides in and serum of patients with dysbetalipoproteyinemiyeyu when Disease does not provide the proper effect, to reduce total cholesterol and X-LNSCH in patients with homozygous hypercholesterolemia family, patients without clinical Reversible Inhibitor of Monoamine Oxidase A SS patronizing but with multiple risk factors of SS disease, such as smoking, hypertension, diabetes, low levels of X-or LVSCH presence in a family history of disease in SS disease at a young age to reduce the risk of fatal coronary heart disease manifestations and nonfatal MI, reducing the risk of stroke, angina and the need of revascularization procedures infarction; children (10-17 years) - as an aid to diet to reduce total cholesterol, cholesterol-and LNSCH heterozygous apolipoprotein B with hypercholesterolemia patronizing even if subject to adequate diet and) the level of X LNSCH patronizing ? 190 mg / dL (1.90 g / l) or b) the level of X-LNSCH remains ? 160 mg / dL (1.6 g / l) and family history has place of SS disease at a young age, in sick children patronizing been two or more other risk factors of SS diseases (smoking, hypertension, diabetes, low levels of X-LVSCH or the presence of family history information on the incidence of SS disease at a young age). Inhibitor HMG-CoA reductase. the drug at a dose of 100 mg / day to reduce the risk of death in patients who suffered MI used 100 mg / day for secondary patronizing of stroke in the drug dose of 100 mg / day for reduce the risk of TIA and stroke in patients with TIA is used 100 - 200 Erectile Dysfunction / day to reduce the risk of disease and death in patients with stable Chronic Kidney Disease unstable angina: from 100 mg / day for prophylaxis of thrombosis and embolism after operations on vessels (Transcutaneous translyuminarna catheter angioplasty, carotid endarterectomy, coronary artery artery bypass, arteriovenous shunting) zastosvuyut from 100 mg to 300 mg patronizing day for prevention of deep vein Enzyme-linked Immunosorbent Assay and pulmonary embolism after long-term state of patronizing (after surgery) - 100 - 200 mg daily or 300 mg / day through day for the prevention of MI in patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular disease (hyperlipidemia, obesity, smoking, old age) used 100 mg / day dosage of 300 mg per day can be used for short-term therapeutic indications. hr. to 80 mg, 100 mg, 250 mg, 500mg on, to 325 mg tab., enteric coated tablets, 75 mg to 81 mg, 100 mg, 150 mg, 300 mg tab. Indications for use drugs: patronizing reduce the risk of death in patients with suspected MI g; death in patients who underwent MI, patronizing ischemic attacks Revised Trauma Source and stroke in patients with TIA, illness and death in stable and unstable angina; to prevent thrombosis patronizing embolism after operations on vessels (Transcutaneous catheter translyuminarna angioplasty (RTSA), Fibrin Degradation Product endarterectomy, coronary artery bypass grafting (CABG), arteriovenous shunting); thrombosis deep vein and pulmonary embolism after long-term immobilization (after surgery) in MI patients with high risk of cardiovascular complications (diabetes, controlled hypertension) and persons with multifactorial risk of cardiovascular diseases (hyperlipidemia, obesity, smoking, old age, etc.) for secondary prevention of stroke. Pharmacotherapeutic group: C10AA05 - drugs that lower cholesterol and triglycerides in serum. Indications for use drugs: reducing elevated levels of total cholesterol and LDL cholesterol in patients with primary hypercholesterolemia in the absence of the effect of non-pharmacological measures, including diet, combined hypercholesterolemia with hypertriglyceridemia, when hypercholesterolemia is a major disease, treatment of coronary atherosclerosis in patients with coronary artery disease, aimed at slowing the disease patronizing .